-+ 0.00%
-+ 0.00%
-+ 0.00%

Fractyl Health posts one-year REVEAL-1 data showing Revita maintains 78% of GLP-1 weight loss after discontinuation

PUBT·06/04/2026 11:02:50
Listen to the news
Fractyl Health posts one-year REVEAL-1 data showing Revita maintains 78% of GLP-1 weight loss after discontinuation
  • Fractyl Health reported one-year open-label REVEAL-1 results for its Revita endoscopic procedure in patients stopping GLP-1 obesity drugs.
  • Patients largely maintained prior drug-driven weight loss over a year, with a subset continuing to lose weight without ongoing medication.
  • The update supports Revita’s positioning as a potential off-ramp for GLP-1 users facing rebound weight gain when therapy ends.
  • Safety looked consistent with routine upper endoscopy, with no procedure-related serious events reported.
  • Next readouts are randomized REMAIN-1 one-year midpoint data in Q3 2026, followed by six-month pivotal topline data in early Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606040700PRIMZONEFULLFEED9731565) on June 04, 2026, and is solely responsible for the information contained therein.